Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2023-04-25 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司2022年年度利润分配方案公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2022 annual profit distribution plan, detailing dividend per share, total dividend amount, and the approval process including board and supervisory opinions. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it focuses on dividend distribution details and related corporate governance approvals. This fits the definition of a Notice of Dividend Amount (DIV). The document length is short (1785 characters), and it is not merely announcing the publication of a report but providing substantive dividend distribution information. Therefore, the appropriate classification is DIV.
2023-04-25 Chinese
江苏浩欧博生物医药股份有限公司关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2022 Annual General Meeting (AGM) of Jiangsu Haobo Biomedical Co., Ltd. It includes details about the meeting date, voting methods, agenda items to be discussed and voted on, and instructions for shareholders. The document does not contain the actual annual report or financial statements but rather the announcement and procedural information related to the AGM. The document length is 3558 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-04-25 Chinese
江苏浩欧博生物医药股份有限公司独立董事关于对外担保情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special statement by independent directors regarding the company's external guarantees for the year 2022. It references regulatory requirements from the China Securities Regulatory Commission and details specific guarantee amounts and terms. The document is a focused explanation on external guarantees, signed by independent directors, and does not contain comprehensive financial statements or broader annual report content. It is not an announcement of a report publication but a standalone explanation related to audit or regulatory compliance matters. Therefore, it fits best under Audit Report / Information (AR). The document length is short but contains substantive content, not just a notice or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). FY 2022
2023-04-25 Chinese
江苏浩欧博生物医药股份有限公司关于第二届董事会第二十四会议相关事项的独立意见
AGM Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding several proposals to be submitted to the 2022 Annual General Meeting (AGM). It includes opinions on the reappointment of the 2023 audit firm, the 2022 profit distribution plan, the 2022 internal control evaluation report, the 2023 guarantee limit, the 2023 director and senior management remuneration plan, and the 2022 use of raised funds. The document is not the full annual report or audit report itself but an independent directors' opinion on AGM agenda items. It is related to the AGM meeting materials and opinions, which fits the category AGM Information (AGM-R). The document length is short (1619 characters), and it is not a report publication announcement or certification. Therefore, the best classification is AGM Information (AGM-R).
2023-04-25 Chinese
江苏浩欧博生物医药股份有限公司关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to reappoint an accounting firm (Lixin CPA Firm) as the auditor for the 2023 fiscal year. It details the qualifications, experience, and independence of the auditor, the audit committee's review and approval, independent directors' opinions, and board and supervisory board resolutions. The document does not contain any financial statements or audit results but is a formal announcement of the auditor reappointment for the upcoming audit period. It is not the audit report itself, nor an annual or interim report. Given the content and length (4198 characters), it fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement about auditor appointment rather than the audit report or financial report itself.
2023-04-25 Chinese
四川敏医健康科技有限公司2022年年度财务报表
Annual Report Classification · 95% confidence The document contains detailed consolidated and parent company balance sheets and income statements for the fiscal year ending December 31, 2022, with extensive financial data and notes. The presence of comprehensive financial statements including assets, liabilities, equity, and profit and loss items indicates this is a full annual financial report. The document length is substantial (15,000 characters), and it includes actual financial data rather than just an announcement or certification. There is no indication that this is a quarterly or interim report, nor is it a short earnings release or a regulatory filing. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.